MedTrace Logo

GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity

NCT07668765 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-06-25

No results posted yet for this study

Summary

Prospective observational cohort study evaluating the early proctologic effects of GLP-1 receptor agonist therapy in morbidly obese patients. Participants will undergo baseline and 3-month anorectal symptom assessment and proctologic examination to evaluate newly developed proctologic diseases and changes in pre-existing symptoms.

Conditions

  • Morbid Obesity
  • Anorectal Diseases
  • Drug-Related Side Effects and Adverse Reactions
  • Constipation
  • Diarrhea

Interventions

DRUG

GLP-1 receptor agonist therapy

Participants will receive GLP-1 receptor agonist treatment as part of routine clinical care. The study does not assign treatment but prospectively evaluates proctologic outcomes following treatment initiation.

Sponsors & Collaborators

  • Gazi University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-04-30
Completion
2027-05-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07668765 on ClinicalTrials.gov